A Phase I Dose-Escalation Study of Danusertib (PHA-739358) Administered as a 24-hour Infusion With and Without G-CSF in a 14-day Cycle in Patients with Advanced Solid Tumors

Por Cohen, Roger B., Jones, Suzanne F., Aggarwal, Charu, von Mehren, Margaret, Cheng, Jonathan, Spigel, David R., Greco, F. Anthony, Mariani, Mariangela, Rocchetti, Maurizio, Ceruti, Roberta, Comis, Silvia, Laffranchi, Bernard, Moll, Jurgen, Burris, Howard A.
Publicado em 2009

Influence of pharmacogenetic variability on the pharmacokinetics and toxicity of the aurora kinase inhibitor danusertib

Por Steeghs, Neeltje, Mathijssen, Ron H. J., Wessels, Judith A. M., de Graan, Anne-Joy, van der Straaten, Tahar, Mariani, Mariangela, Laffranchi, Bernard, Comis, Silvia, de Jonge, Maja J. A., Gelderblom, Hans, Guchelaar, Henk-Jan
Publicado em 2010